Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10316
Title: Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Austin Authors: Damianovich, D;Adena, M;Tebbutt, Niall C 
Affiliation: Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 6-Feb-2007
Publication information: British Journal of Cancer 2007; 96(4): 546-50
Abstract: Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC). However, patients enrolled in clinical studies represent a restricted population and little is known about the use of O and I in the general population and the subsequent outcomes outside clinical studies. We used the Australian Health Insurance Commission (HIC) database to describe prescribing patterns of O and I and their impact on survival in all patients with 5-fluorouracil (5-FU) refractory CRC in Australia in 2002 and 2003. In 2999 patients, there was a marked increase in initial treatment with O rather than I; 48% of patients received O first in 2002 vs 66% in 2003 (P<0.001). Overall 40-45% of patients received both O and I; however, younger patients were more likely to receive both drugs (P<0.001). After 5-FU failure and treatment with O or I, the proportion of patients surviving 6 or 12 months was estimated to be 0.67 (95% CI, 0.66-0.69) and 0.42 (95% CI, 0.40-0.44), respectively. Survival was superior for patients who received both O and I; however, the sequence of agents had no impact. Older patients (> or =70 years) had inferior survival no matter which drug was used as initial treatment. Analysis of the Australian HIC database provides a valuable means of assessing patterns of use and outcomes of new therapies.
Gov't Doc #: 17285136
URI: https://ahro.austin.org.au/austinjspui/handle/1/10316
DOI: 10.1038/sj.bjc.6603590
Journal: British Journal of Cancer
URL: https://pubmed.ncbi.nlm.nih.gov/17285136
Type: Journal Article
Subjects: Age Distribution
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic use
Australia.epidemiology
Camptothecin.administration & dosage.adverse effects.analogs & derivatives
Cohort Studies
Colorectal Neoplasms.drug therapy.mortality.secondary
Databases, Factual
Disease Progression
Drug Resistance, Neoplasm
Drug Utilization.trends
Female
Fluorouracil.adverse effects.therapeutic use
Follow-Up Studies
Humans
Male
Middle Aged
National Health Programs.statistics & numerical data
Organoplatinum Compounds.administration & dosage.adverse effects
Outcome Assessment (Health Care).statistics & numerical data
Physician's Practice Patterns.trends
Prognosis
Randomized Controlled Trials as Topic.statistics & numerical data
Recurrence
Sex Distribution
Survival Analysis
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on May 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.